NEWSLETTER NO. 7

BOSTON Trials Awareness Raised by the Pulmonary Fibrosis Foundation

In their newly developed Clinical Trials Newsletter, the Pulmonary Fibrosis Foundation (PFF) highlighted the BOSTON trials in the October issue. The patient organization developed this newsletter to inform their patient community about three clinical trials per month. The posting provides a summary of information, as well as a link to the clinicaltrials.gov website. The PFF also features a PFF Clinical Trial Finder on their website. This tool provides a search function for patients to look for studies they may have an interest in. Our team welcomes this encouraging recognition and spread of awareness for bronchiolitis obliterans syndrome and the BOSTON trials. More information is also on the PFF website here.

Replay of Clinical Trial Participation Webinar Now Available

On October 20th, a webinar on the topic of “Clinical Trial Participation” was broadcasted live. This event was a collaborative effort between the Lung Transplant Foundation and Breath Therapeutics, a Zambon company. The webinar featured an overview of clinical trials, a lung transplant recipient’s perspective, and an introduction to the BOSTON trials. The targeted audience for the session was lung transplanted individuals and their caregivers. The replay of the webinar is available here.

How Do You Like the Newsletters?

Feedback (positive or constructive) is welcome at boston.sitesupport@zambongroup.com.

Help Needed, Questions or Suggestions?

The development program for inhaled L-CsA for the treatment of bronchiolitis obliterans is very important to Zambon.

LabCorp is responsible for the operational conduct of the studies and your LabCorp contact should be your first point of contact for questions.

However, please do not hesitate to get in touch with us directly if you’d like. Emails addressed to boston.sitesupport@zambongroup.com will reach the Zambon study team and will be answered promptly.

Newsletters are for BOSTON clinical site personnel only and not intended to be shared with patients, trial participants or any external audiences.